- Pumps and flow paths
- Microfluidic channels
- Filtration systems
- Diagnostic and processing devices
Application Domain 09
Medical & Biotech Fluid Systems
Exploring governed micro- and mesoscale surfaces in biomedical fluid handling.
Research-stage application · performance validation pending
Application Thesis
A governed architecture—not a universal surface treatment.
DDM treats cell geometry, spacing, orientation, density, and placement as application-dependent variables. Candidate configurations must be tuned to the local flow regime, surface geometry, operating envelope, materials, and performance objective.
Public descriptions communicate the research hypothesis and validation strategy. Detailed geometry ranges, configuration logic, and application-specific design rules remain controlled technical information.
Potential if Validated
At biomedical scale, flow quality can become product quality—and sometimes patient risk.
DDM is investigating whether governed micro- and mesoscale surfaces can influence shear exposure, residence time, pulsation, maldistribution, recirculation, interfacial behavior, mixing, bubbles, deposition, and pressure loss. The opportunity spans medical devices and bioprocess systems, but no local fluid result may be presented as a safety, diagnostic, therapeutic, or clinical benefit without device-specific biological, analytical, and regulatory evidence.
Govern delicate transport
Test velocity gradients, wall shear, scalar mixing, residence-time distribution, pulsation, recirculation, interfaces, bubble behavior, and deposition under defined fluids and boundary conditions.
Measure verified function
Quantify flow accuracy, pressure drop, channel uniformity, clearance or transfer performance, hemolysis indices, cell viability, fouling, alarm behavior, and repeatability.
Establish safe translation
Connect supported results to device reliability, consumables, batch consistency, throughput, battery demand, process yield, and clinical performance only through the required verification, validation, and regulatory pathway.
Where DDM Could Apply
From blood-contacting pumps to high-volume bioprocessing.
The geometry, material, scale, fluid, contact duration, sterilization process, cleaning method, and failure consequences differ radically. DDM would be treated as a controlled design input—not a universal biomedical texture.
Blood pumps & assist devices
Rotary and pulsatile blood pumps, extracorporeal circuits, oxygenators, and circulatory-support flow paths where shear history, residence time, heat, hemolysis, and thrombogenicity are safety-critical.
Dialysis & filtration
Dialyzers, hemofiltration cartridges, blood and dialysate manifolds, fiber bundles, access components, and return paths challenged by maldistribution, pressure variation, clotting, and fouling.
Infusion & drug delivery
Infusion-pump cassettes, IV manifolds, valves, catheters, wearable delivery systems, and low-flow channels where dose accuracy, occlusion response, bubbles, backflow, and material compatibility matter.
Diagnostics & microfluidics
Lab-on-chip, PCR, immunoassay, sample-preparation, droplet, and reagent-handling devices where microliter-scale flow, interfaces, mixing, carryover, and clogging determine repeatability.
Bioreactors & cell processing
Perfusion loops, single-use assemblies, cell-culture systems, harvest lines, media distribution, and downstream processing where shear exposure, oxygen transfer, mixing, sterility, and cell viability interact.
Pharma & laboratory systems
Formulation, fill-finish, chromatography, filtration, nanoparticle production, sampling, and analytical flow paths requiring controlled transport, cleanability, extractables assessment, and process validation.
Representative Deployment Zones
Treat the sensitive flow structure while preserving sterility and manufacturability.
- A
Pump and actuation interfacesRotor passages, pump heads, peristaltic cassettes, valves, and transition zones associated with shear peaks, pulsation, backflow, and heat.
- B
Manifolds and distribution headersFlow splitting, channel maldistribution, pressure balance, dead volume, mixing, carryover, priming, and bubble migration.
- C
Microchannels and assay regionsLow-Reynolds-number transport, diffusion length, droplet formation, interfaces, clogging, surface chemistry, optical access, and analytical repeatability.
- D
Membranes, fibers, and filtersPerfusion uniformity, concentration polarization, transmembrane pressure, fouling, clotting, mass transfer, and cleaning or disposal.
- E
Connectors, traps, ports, and returnsRecirculation, bubble capture or release, stagnation, residual volume, leakage, aseptic connection, sampling, and complete drainage.
Engineering Translation
Lower computed shear does not automatically mean lower hemolysis, thrombosis, or cell damage.
Biological response depends on stress magnitude, exposure time, repeated passage, fluid composition, temperature, surface chemistry, contact activation, device interactions, and the measurement method. Mixing, dose accuracy, filtration, and fouling likewise require their own device-level endpoints and acceptance criteria.
Illustrative Shear-Exposure Lens
What a validated reduction in a defined peak-shear metric could mean.
Assumed engineering case: a baseline peak value of 100 Pa at a specified location, fluid, flow rate, temperature, and test method. The cases below are arithmetic research thresholds—not measured DDM performance, safe limits, or predictions of hemolysis, platelet response, cell survival, or clinical outcome.
Conservative threshold
5%
modeled peak-shear reduction
- Resulting peak metric
- 95 Pa
- Absolute change
- 5 Pa lower
- Research role
- screening target
Target threshold
15%
modeled peak-shear reduction
- Resulting peak metric
- 85 Pa
- Absolute change
- 15 Pa lower
- Research role
- development target
High-impact threshold
25%
modeled peak-shear reduction
- Resulting peak metric
- 75 Pa
- Absolute change
- 25 Pa lower
- Research role
- stretch target
Illustrative Flow-Uniformity Lens
Uniform distribution can matter across fibers, channels, wells, and culture zones.
For a representative parallel-flow device with a baseline channel-to-channel coefficient of variation of 20%, a verified 10%, 25%, or 40% relative reduction would yield CV values of 18%, 15%, or 12%. Whether that improves dialysis clearance, oxygen transfer, assay precision, reagent use, or cell culture must be measured separately with the applicable device endpoint.
10%CV 20% → 18%
25%CV 20% → 15%
40%CV 20% → 12%
Pressure, Bubbles & Fouling Opportunity
A useful surface must improve the device without creating a new failure mode.
For a defined 100 kPa pressure-drop baseline, verified reductions of 5%, 10%, or 20% would equal 5, 10, or 20 kPa less loss. Electrical savings are not one-to-one and depend on flow, pump efficiency, controls, and duty cycle. Bubble nucleation, adhesion and clearance; protein deposition; clotting; biofilm; extractables; particles; and occlusion behavior require separate tests.
5%5 kPa less pressure drop
10%10 kPa less pressure drop
20%20 kPa less pressure drop
The DDM Validation Gate
Biomedical flow claims require fluid, device, biological, manufacturing, and regulatory evidence.
DDM must demonstrate repeatable performance across geometry scale, Reynolds and Womersley regimes where applicable, pulsation, pressure, temperature, viscosity, non-Newtonian behavior, hematocrit or cell density, proteins, particles, gas-liquid interfaces, priming, orientation, occlusion, transients, tolerances, surface finish, aging, extractables and leachables, sterilization, cleaning, biocompatibility, fouling, clotting, hemolysis, cell viability, assay chemistry, packaging, shelf life, and misuse conditions. Development should progress from validated CFD and benchtop metrology to representative fluids, biological testing, design verification, risk management, process validation, and the applicable FDA or other regulatory submission pathway.
Authoritative Benchmarks & Calculation Basis
FDA — Hemolysis CFD Validation DatasetFDA provides inter-laboratory hemolysis data for generic nozzle and blood-pump geometries, including plasma-free hemoglobin as a function of time and flow rate—an evidence model for coupling simulation with bench testing.Open official source ↗FDA — Blood-Contacting Device AssessmentFDA guidance emphasizes that device geometry, surface roughness, defects, materials, contact type, and duration affect biological assessment; a fluid-path change therefore requires more than favorable flow simulation.Open official source ↗NIST — Passive Microfluidic MeasurementNIST identifies flow rate as a critical measure of microfluidic-system performance and notes that flow changes can reveal failures—supporting traceable, device-level metrology for DDM trials.Open official source ↗FDA — Medical-Device SterilizationFDA lists multiple established sterilization approaches; any DDM material and geometry must be validated for the selected process, packaging, sterility assurance, residues, and repeated exposure where applicable.Open official source ↗
Shear arithmetic: 100 Pa baseline × modeled reduction. Uniformity arithmetic: 20% baseline coefficient of variation × relative reduction. Pressure arithmetic: 100 kPa baseline × modeled reduction. Every percentage is a DDM research threshold, not achieved performance or a clinical claim.
Research Questions
What must be established before performance can be claimed.
Can controlled surface interaction improve mixing, transport, or flow stability at relevant scales?
How do shear sensitivity, sterility, fouling, and biocompatibility constrain use?
Which concepts justify specialized laboratory investigation?
Validation Path
From application hypothesis to defensible evidence.
- 01
Define application and safety requirements
- 02
Model relevant non-Newtonian or multiphase behavior
- 03
Assess cleanability and biocompatibility constraints
- 04
Advance only supported concepts toward controlled bench testing
Evidence status
No application-specific performance figures are presented here as demonstrated results. Quantitative claims will be published only when supported by traceable computational or experimental evidence and clearly stated boundary conditions.
Application-Specific Collaboration
Evaluate alignment with this research domain.
DDM welcomes conversations with government programs, laboratories, universities, OEMs, and technical partners.
Discuss this application